AXIN2 rs2240308 polymorphism contributes to increased cancer risk: evidence based on a meta-analysis

Cancer Cell International

Hong Xu²  Lili Wei²  Shengbo Zhu¹  Chunming Liu¹  Shifu Tang¹  Yifan Sun¹  Zhitong Wu³ 

[1] Department of Clinical Laboratory, Liuzhou Hospital of Traditional Chinese Medicine, 32 Jiefang North Road, Liuzhou 545001, , Guangxi, People’s Republic of China;Department of Science and Education, Liuzhou Hospital of Traditional Chinese Medicine, 32 Jiefang North Road, Liuzhou 545001, , Guangxi, People’s Republic of China;Department of Clinical Laboratory, Guigang City People’s Hospital, 1 Zhongshan Middle Road, Guigang 537100, , Guangxi, People’s Republic of China

关键词: Meta-analysis;    Risk;    Cancer;    Polymorphism;    AXIN2;   

Others  :  1219325
DOI  :  10.1186/s12935-015-0219-8

 received in 2014-12-12, accepted in 2015-06-22,  发布年份 2015

【 摘 要 】

Background

Variants in the axis inhibition 2 (AXIN2) gene might alter the protein’s structure or function or create a multiprotein destruction complex in the Wnt signaling pathway and thus affect an individual’s susceptibility to cancer. The objective of this study is to evaluate broadly the evidence available for the AXIN2 rs2240308 polymorphism and risk of cancer.

Methods

A comprehensive literature search was undertaken for eligible studies in Embase, PubMed, and Cochrane Library up to Nov 30, 2014. Odds ratios (ORs) and the corresponding 95 % confidence intervals (CIs) were used to measure the strength of the models.

Results

Eight articles (10 case-control studies with 1,502 cases and 1,590 controls) were included in this analysis. Overall, the AXIN2 rs2240308 polymorphism was associated with a significant increase in the risk of cancer (G allele vs. A allele: OR = 1.21, 95 % CI = 1.05–1.40, I ²  = 39.5 % and P _Q  = 0.094 for heterogeneity; GG vs. AA: OR = 1.30, 95 % CI = 1.04–1.63, I ²  = 35.9 % and P _Q  = 0.121 for heterogeneity; GG vs. GA + AA: OR = 1.36, 95 % CI = 1.17–1.58, I ²  = 19.5 % and P _Q  = 0.263 for heterogeneity). Asian populations showed similar results. Stratified analysis by cancer types indicated that the AXIN2 rs2240308 polymorphism increases the risk of lung cancer (G allele vs. A allele: OR = 1.36, 95 % CI = 1.17–1.59; GA vs. AA: OR = 1.43, 95 % CI = 1.01–2.02; GG vs. AA: OR = 1.93, 95 % CI = 1.36–2.75; GG + GA vs. AA: OR = 1.65, 95 % CI = 1.18–2.30; GG vs. GA + AA: OR = 1.45, 95 % CI = 1.18–1.79. All I ²  < 50 % and P _Q  > 0.100 for heterogeneity).

Conclusions

This study showed that the AXIN2 rs2240308 polymorphism contribute to increasing the risk of cancer, especially lung cancer in Asian populations.

【 授权许可】

   
2015 Wu et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

【 参考文献 】

• [1]Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell. 2012; 149(6):1192-205.
• [2]He Y, Liu Z, Qiao C, Xu M, Yu J, Li G. Expression and significance of Wnt signaling components and their target genes in breast carcinoma. Mol Med Rep. 2014; 9(1):137-43.
• [3]Schaal U, Grenz S, Merkel S, Rau TT, Hadjihannas MV, Kremmer E et al.. Expression and localization of axin 2 in colorectal carcinoma and its clinical implication. Int J Color Dis. 2013; 28(11):1469-78.
• [4]Behrens J, Jerchow BA, Wurtele M, Grimm J, Asbrand C, Wirtz R et al.. Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science (New York, NY). 1998; 280(5363):596-9.
• [5]Hart MJ, de los Santos R, Albert IN, Rubinfeld B, Polakis P. Downregulation of β-catenin by human Axin and its association with the APC tumor suppressor, β-catenin and GSK3β. Curr Biol. 1998; 8(10):573-81.
• [6]Xu H-T, Wang L, Lin D, Liu Y, Liu N, Yuan X-M et al.. Abnormal β-Catenin and Reduced Axin Expression Are Associated With Poor Differentiation and Progression in Non–Small Cell Lung Cancer. Am J Clin Pathol. 2006; 125(4):534-41.
• [7]Dong X, Seelan RS, Qian C, Mai M, Liu W. Genomic structure, chromosome mapping and expression analysis of the human AXIN2 gene. Cytogenet Cell Genet. 2001; 93(1-2):26-8.
• [8]Liu W, Dong X, Mai M, Seelan RS, Taniguchi K, Krishnadath KK et al.. Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling. Nat Genet. 2000; 26(2):146-7.
• [9]Wang X, Goode EL, Fredericksen ZS, Vierkant RA, Pankratz VS, Liu-Mares W et al.. Association of genetic variation in genes implicated in the beta-catenin destruction complex with risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2008; 17(8):2101-8.
• [10]Gunes EG, Pinarbasi E, Pinarbasi H. AXIN2 polymorphism and its association with astrocytoma in a Turkish population. Mol Med Rep. 2010; 3(4):705-9.
• [11]Liu D, Li L, Yang Y, Liu W, Wu J. The Axin2 rs2240308 polymorphism and susceptibility to lung cancer in a Chinese population. Tumour Biol. 2014; 35(11):10987-10991.
• [12]Mostowska A, Pawlik P, Sajdak S, Markowska J, Pawalowska M, Lianeri M et al.. An analysis of polymorphisms within the Wnt signaling pathway in relation to ovarian cancer risk in a Polish population. Mol Diag Ther. 2014; 18(1):85-91.
• [13]Pinarbasi E, Gunes EG, Pinarbasi H, Donmez G, Silig Y. AXIN2 polymorphism and its association with prostate cancer in a Turkish population. Med oncol (Northwood, London, England). 2011; 28(4):1373-8.
• [14]Gunes EG, Pinarbasi E, Pinarbasi H, Silig Y. Strong association between lung cancer and the AXIN2 polymorphism. Mol Med Rep. 2009; 2(6):1029-35.
• [15]Ma C, Liu C, Huang P, Kaku H, Chen J, Guo K et al.. Significant association between the Axin2 rs2240308 single nucleotide polymorphism and the incidence of prostate cancer. Oncol Lett. 2014; 8(2):789-94.
• [16]Kanzaki H, Ouchida M, Hanafusa H, Yano M, Suzuki H, Aoe M et al.. Single nucleotide polymorphism of the AXIN2 gene is preferentially associated with human lung cancer risk in a Japanese population. Int J Mol Med. 2006; 18(2):279-84.
• [17]Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4):264-9.
• [18]Ioannidis JP, Boffetta P, Little J, O’Brien TR, Uitterlinden AG, Vineis P et al.. Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol. 2008; 37(1):120-32.
• [19]Thakkinstian A, McEvoy M, Minelli C, Gibson P, Hancox B, Duffy D et al.. Systematic review and meta-analysis of the association between β2-adrenoceptor polymorphisms and asthma: a HuGE review. Am J Epidemiol. 2005; 162(3):201-11.
• [20]Ye X-H, Bu Z-B, Feng J, Peng L, Liao X-B, Zhu X-L, et al. Association between the TP53 polymorphisms and lung cancer risk: a meta-analysis. Mol Biol Rep. 2013;1–13.
• [21]Higgins J, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Stat Med. 2002; 21(11):1539-58.
• [22]Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557.
• [23]Liu X, Li S, Lin XJ, Yan KK, Zhao LY, Bao HH et al.. Association between ITGA3, TP53INP2, and AXIN2 gene polymorphism and papillary thyroid carcinoma. J Jilin Univ Med Edition. 2014; 40(2):384-8.
• [24]Webster MT, Rozycka M, Sara E, Davis E, Smalley M, Young N et al.. Sequence variants of the axin gene in breast, colon, and other cancers: an analysis of mutations that interfere with GSK3 binding. Genes Chromosom Cancer. 2000; 28(4):443-53.
• [25]MacDonald BT, Tamai K, He X. Wnt/β-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009; 17(1):9-26.
• [26]Nelson WJ, Nusse R. Convergence of Wnt, ß-catenin, and cadherin pathways. Science (New York, NY). 2004; 303(5663):1483-7.
• [27]Tseng R-C, Lin R-K, Wen C, Tseng C, Hsu H-S, Hsu W et al.. Epigenetic silencing of AXIN2/betaTrCP and deregulation of p53-mediated control lead to wild-type β-catenin nuclear accumulation in lung tumorigenesis. Oncogene. 2008; 27(32):4488-96.
• [28]Furuhashi M, Yagi K, Yamamoto H, Furukawa Y, Shimada S, Nakamura Y et al.. Axin facilitates Smad3 activation in the transforming growth factor β signaling pathway. Mol Cell Biol. 2001; 21(15):5132-41.
• [29]Ikushima H, Miyazono K. TGF beta signalling: a complex web in cancer progression. Nat Rev Cancer. 2010; 10(6):415-24.
• [30]Yang L-H, Xu H-T, Li Q-C, Jiang G-Y, Zhang X-P, Zhao H-Y et al.. Abnormal hypermethylation and clinicopathological significance of Axin gene in lung cancer. Tumor Biol. 2013; 34(2):749-57.
• [31]Kordi Tamandani MK, Sobti RC, Shekari M, Mukesh M, Suri V. Expression and polimorphism of IFN-gamma gene in patients with cervical cancer. Exp Oncol. 2008; 30(3):224-9.
• [32]Gangwar R, Pandey S, Mittal RD. Association of interferon-gamma +874A polymorphism with the risk of developing cervical cancer in north-Indian population. BJOG. 2009; 116(12):1671-7.
• [33]Lee JE, Lee SJ, Namkoong SE, Um SJ, Sull JW, Jee SH et al.. Gene-gene and gene-environmental interactions of p53, p21, and IRF-1 polymorphisms in Korean women with cervix cancer. Int J Gynecol Cancer. 2004; 14(1):118-25.
• [34]Qin X, Peng Q, Chen Z, Deng Y, Huang S, Xu J et al.. The association between MTHFR gene polymorphisms and hepatocellular carcinoma risk: a meta-analysis. PLoS ONE. 2013; 8(2): Article ID e56070